| Literature DB >> 32066996 |
Joshua D Kaggie1, Surrin Deen1, Dimitri A Kessler1, Mary A McLean2, Guido Buonincontri3, Rolf F Schulte4, Helen Addley1, Evis Sala5, James Brenton2, Martin J Graves1, Ferdia A Gallagher1.
Abstract
Multiparametric magnetic resonance imaging (MRI) can be used to characterize many cancer subtypes including ovarian cancer. Quantitative mapping of MRI relaxation values, such as T 1 and T 2 mapping, is promising for improving tumor assessment beyond conventional qualitative T 1- and T 2-weighted images. However, quantitative MRI relaxation mapping methods often involve long scan times due to sequentially measuring many parameters. Magnetic resonance fingerprinting (MRF) is a new method that enables fast quantitative MRI by exploiting the transient signals caused by the variation of pseudorandom sequence parameters. These transient signals are then matched to a simulated dictionary of T 1 and T 2 values to create quantitative maps. The ability of MRF to simultaneously measure multiple parameters, could represent a new approach to characterizing cancer and assessing treatment response. This feasibility study investigates MRF for simultaneous T 1, T 2, and relative proton density (rPD) mapping using ovarian cancer as a model system.Entities:
Keywords: Cancer applications; clinical imaging; imaging techniques; magnetic resonance imaging (MRI); oncology; ovarian cancer
Year: 2019 PMID: 32066996 PMCID: PMC7025887 DOI: 10.1109/TRPMS.2019.2905366
Source DB: PubMed Journal: IEEE Trans Radiat Plasma Med Sci ISSN: 2469-7303
Fig. 1(a) FA and TR list used during acquisition and simulation. (b) Five spokes showing the k-space acquisition with golden angle spiral interleaves. (c) Sample dictionary of simulated signals showing the intensity of the MRF signal for each k-space spiral acquisition (frame), for different TRs and FAs.
Ranges and Incremental Changes for T1 and T2
| Parameter | Range (ms) | Increment (ms) |
|---|---|---|
| T1 | 10 – 400 | 10 |
| 400 - 4000 | 20 | |
| T2 | 2 - 20 | 1 |
| 20 - 400 | 2 | |
| 400 - 2500 | 20 |
Fig. 2T1 and T2 values measured in the ISMRM/NIST phantom vials (of the T1-slice and T2-slice of the phantom, respectively). Each horizontal line corresponds to a single vial, which would be constant with repeatable and reproducible conditions. The labels indicate values obtained from: Published values in the NIST manual; Traditional quantification with standard T2 multiecho spin echo (MESE) or T1 VFA mapping; using the PET/MR; on the clinical system (Baseline), Repeated after an hour and after 1 week, and using a reduced number of Frames (1/2 or 1/4) when compared with baseline (frames = 979).
Difference With Baseline (Mean ± StdDev)
| ΔT1/T1,Baseline (%) | ΔT2/T2,Baseline (%) | |
|---|---|---|
| Published NIST | -28 ± 16 | -38 ±34 |
| T1-VFA or T2-MESE | 25 ± 68 | -39 ± 14 |
| PET/MR | 26 ± 38 | 17 ± 32 |
| Baseline (979 Frames) | 0 ± 0 | 0 ± 0 |
| Repeat, 1 Hour | -4 ± 19 | 0.2 ± 3.9 |
| Repeat, 1 Week | 7 ± 19 | -9 ± 19 |
| ½ (=489) Frames | 3 ± 36 | 2 ± 11 |
| ¼ (=244) Frames | -1 ± 5 | -18 ± 24 |
Fig. 3T1 and T2 values measured in the ISMRM/NIST phantom with the number of singular vectors for SVD compression (= rank) varied between 2 and 20 before matching. Each horizontal line represents a static T1 or T2 value. Both plots show values from vials in the T2-slice. Longer T1 and T2 values (>0.5 s) are accurate with rank > 3, while shorter relaxation values require rank > 16 to have less than 1% difference with rank 20.
Fig. 4Coronal T1, T2, and PD quantitative maps of the four patients with (a)–(c) borderline serous and (d)–(l) high grade tumors. One of the HGSOC tumors had extensive ascites, and the HGSOC patient who had treatment had no histological evidence of remaining carcinoma (j)–(l). The T2 images (b), (e), (h), and (k) are shown with a maximum scale of 600 ms, although the dictionary was created up to values of 2.5 s.
Mean Relaxation Values of Different Tumor Types
| Tumour | T1 (ms) | T2 (ms) |
|---|---|---|
| Borderline serous | 2465 ± 101 | 225 ± 34 |
| HGSOC | 1975 ± 191 | 94 ± 15 |
| HGSOC with ascites | 1621 ± 46 | 174 ± 26 |
| HGSOC post treatment | 1059 ± 55 | 116 ± 12 |